Last reviewed · How we verify
Feeling agitated — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Versed | midazolam | Generic (originally Roche) | Benzodiazepine (short-acting) | Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2 | 1985-12-20 | |
| Versed | Midazolam Hydrochloride | Takeda Pharmaceutical Company Limited | Benzodiazepine | GABA A receptor alpha-5/beta-2/gamma-2 | 1985-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Generic (originally Roche) · 1 drug in Feeling agitated
- Takeda Pharmaceutical Company Limited · 1 drug in Feeling agitated
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Feeling agitated:
- Feeling agitated treatment updates — RSS
- Feeling agitated treatment updates — Atom
- Feeling agitated treatment updates — JSON
Cite this brief
Drug Landscape (2026). Feeling agitated — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/feeling-agitated. Accessed 2026-06-10.
Related
- Feeling agitated full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing